Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital’s Stephen Dunn
Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital’s Stephen Dunn
By
on
February 20, 2015
·
Summary
In 2015, the focus of the checkpoint inhibitor space will be on additional cancer types, beyond melanoma, as well as on collaborations and combinations.
The financial resources needed to develop an advantage in the anti-PD-1/PD-L1 space are now beyond the reach of most smaller biotechs.
The entire patent landscape in immuno-oncology is a bit murky at the present time, and developments on the legal front have the possibility of impacting stocks in the future.
Every researcher I’ve spoken with, at both large pharmaceutical and small biotech companies, believes these immune strategies will result in a quantum leap for cancer patient survival.
Immuno-oncology-disabling cancer’s defenses so that a patient’s own immune system can seek it out and destroy it-took center stage in the drug development world in 2014. Stephen Dunn of LifeTech Capital believes that preeminence will continue in 2015, bolstered by new drug approvals, new targets and new combination immunotherapies that increase potency. In this interview with The Life Sciences Report, Dunn outlines how companies large and small are leveraging these therapies, and where investors should look for opportunity in the sector.
About
Testing
Mail
|
Web
|
More Posts (3435)
Share. Facebook Google+ Pinterest LinkedIn Tumblr Email
View post:
Immuno-Oncology Promises Continued Wealth And Health: LifeTech Capital’s Stephen Dunn
See which stocks are being affected by Social Media
